The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: A systematic review and individual patient data meta-analysis.
 
Stepan M. Esagian
No Relationships to Disclose
 
Ioannis A. Ziogas
No Relationships to Disclose
 
Dimitrios Kosmidis
No Relationships to Disclose
 
Mohammad D. Hossain
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Nektar; Neoleukin Therapeutics; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb; Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)